Skip to content

Contact +44 (0) 20 7060 7474 email us

Healthcare

Healthcare Market

In this section you will find information products, including market research, on the Healthcare Market, including latest technologies, company profiles, biopharmaceuticals, market data and information covering Europe, the UK, North America and Asia.

Stay up-to-date with new products added to this category »
Title Publication Date Price
Nektar Therapeutics - Financial and Strategic Analysis Review
June 2009 £76
Neoprobe Corporation - Financial and Strategic Analysis Review
June 2009 £76
Medicis Pharmaceutical Corporation - Financial and Strategic Analysis Review
June 2009 £76
MedCath Corporation - Financial and Strategic Analysis Review
June 2009 £76
MONOGRAM BIOSCIENCES, INC. - Financial and Strategic Analysis Review
June 2009 £76
Martek Biosciences Corporation - Financial and Strategic Analysis Review
June 2009 £76
Neurocrine Biosciences, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Novartis AG - Financial and Strategic Analysis Review
June 2009 £76
Universal American Corp. - Financial and Strategic Analysis Review
June 2009 £76
Vasogen Inc. - Financial and Strategic Analysis Review
June 2009 £76
Triple-S Management Corporation - Financial and Strategic Analysis Review
June 2009 £76
Southern Cross Healthcare Group PLC - Financial and Strategic Analysis Review
June 2009 £76
Perot Systems Corporation - Financial and Strategic Analysis Review
June 2009 £76
QLT Inc. - Financial and Strategic Analysis Review
June 2009 £76
LifePoint Hospitals, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Labopharm Inc. - Financial and Strategic Analysis Review
June 2009 £76
Grifols, S.A. - Financial and Strategic Analysis Review
June 2009 £76
Halozyme Therapeutics - Financial and Strategic Analysis Review
June 2009 £76
Gilead Sciences, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Genomic Health, Inc. - Financial and Strategic Analysis Review
June 2009 £76
GPC Biotech AG - Financial and Strategic Analysis Review
June 2009 £76
GenVec, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Illumina, Inc. - Financial and Strategic Analysis Review
June 2009 £76
InSite Vision Incorporated - Financial and Strategic Analysis Review
June 2009 £76
Inspire Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Javelin Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Inovio Biomedical Corporation - Financial and Strategic Analysis Review
June 2009 £76
Inhibitex, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Incyte Corporation - Financial and Strategic Analysis Review
June 2009 £76
Infinity Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
June 2009 £76
deCODE genetics, Inc. - Financial and Strategic Analysis Review
June 2009 £76
eResearchTechnology, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Anadys Pharmaceuticals, Inc - Financial and Strategic Analysis Review
June 2009 £76
Ardea Biosciences, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Amylin Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Amicus Therapeutics, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Alnylam Pharmaceuticals, Inc - Financial and Strategic Analysis Review
June 2009 £76
AmerisourceBergen Corporation - Financial and Strategic Analysis Review
June 2009 £76
Arena Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Ariad Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
June 2009 £76
BioMarin Pharmaceutical Inc. - Financial and Strategic Analysis Review
June 2009 £76
BioSpecifics Technologies Corp. - Financial and Strategic Analysis Review
June 2009 £76
BioCryst Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
June 2009 £76
BELLUS Health Inc - Financial and Strategic Analysis Review
June 2009 £76
Auxilium Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Averion International Corp. - Financial and Strategic Analysis Review
June 2009 £76
Almost Family, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Allos Therapeutics, Inc - Financial and Strategic Analysis Review
June 2009 £76
ALK-Abello AS - Financial and Strategic Analysis Review
June 2009 £76
ARQULE, INC - Financial and Strategic Analysis Review
June 2009 £76
AEterna Zentaris Inc. - Financial and Strategic Analysis Review
June 2009 £76
ADVENTRX Pharmaceuticals - Financial and Strategic Analysis Review
June 2009 £76
etrials Worldwide, Inc. - Financial and Strategic Analysis Review
June 2009 £76
ACADIA Pharmaceuticals Inc. - Financial and Strategic Analysis Review
June 2009 £76
ARYx Therapeutics - Financial and Strategic Analysis Review
June 2009 £76
Achillion Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Akorn, Inc - Financial and Strategic Analysis Review
June 2009 £76
Alexion Pharmaceuticals - Financial and Strategic Analysis Review
June 2009 £76
Advanced Life Sciences holdings, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Adolor Corp. - Financial and Strategic Analysis Review
June 2009 £76
Acorda Therapeutics, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Active Biotech AB - Financial and Strategic Analysis Review
June 2009 £76
GENTIUM S.p.A. - Financial and Strategic Analysis Review
June 2009 £76
Exelixis, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Acura Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Addex Pharmaceuticals - Financial and Strategic Analysis Review
June 2009 £76
Actelion Ltd - Financial and Strategic Analysis Review
June 2009 £76
Access Pharmaceuticals - Financial and Strategic Analysis Review
June 2009 £76
AMDL, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Accelrys, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Adherex Technologies Inc. - Financial and Strategic Analysis Review
June 2009 £76
Advaxis, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Altus Pharmaceuticals Inc. - Financial and Strategic Analysis Review
June 2009 £76
Amorfix Life Sciences Ltd. - Financial and Strategic Analysis Review
June 2009 £76
Alseres Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Alizyme plc - Financial and Strategic Analysis Review
June 2009 £76
Albany Molecular Research, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Alexza Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
June 2009 £76
3SBio Inc. - Financial and Strategic Analysis Review
June 2009 £76
US Oncology, Inc. - Strategic Analysis Review
June 2009 £76
HCA, Inc. - Strategic Analysis Review
June 2009 £76
Highmark Inc. - Strategic Analysis Review
June 2009 £76
E. I. du Pont de Nemours and Company - Strategic Analysis Review
June 2009 £76
Detroit Medical Center - Strategic Analysis Review
June 2009 £76
Apotex, Inc. - Strategic Analysis Review
June 2009 £76
Carolinas Healthcare system - Strategic Analysis Review
June 2009 £76
Iowa Health System - Strategic Analysis Review
June 2009 £76
Les Laboratoires Servier - Strategic Analysis Review
June 2009 £76
The Cleveland Clinic Foundation - Strategic Analysis Review
June 2009 £76
UPMC - Strategic Analysis Review
June 2009 £76
St. Joseph Health System - Strategic Analysis Review
June 2009 £76
Mission Pharmacal Company - Strategic Analysis Review
June 2009 £76
Lpath, Inc. - Strategic Analysis Review
June 2009 £76
MedImmune, Inc. - Strategic Analysis Review
June 2009 £76
Anesiva, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Ark Therapeutics Group plc - Financial and Strategic Analysis Review
June 2009 £76
Commonwealth Biotechnologies, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Covance Inc. - Financial and Strategic Analysis Review
June 2009 £76
Clarient, Inc. - Financial and Strategic Analysis Review
June 2009 £76
China Sky One Medical, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Cerus Corporation - Financial and Strategic Analysis Review
June 2009 £76
Chembio Diagnostic, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Cytori Therapeutics, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Echo Therapeutics, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Eurand N.V. - Financial and Strategic Analysis Review
June 2009 £76
Exact Sciences Corporation - Financial and Strategic Analysis Review
June 2009 £76
Epigenomics AG - Financial and Strategic Analysis Review
June 2009 £76
EpiCept Corporation - Financial and Strategic Analysis Review
June 2009 £76
Emergent BioSolutions Inc. - Financial and Strategic Analysis Review
June 2009 £76
EntreMed, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Cepheid - Financial and Strategic Analysis Review
June 2009 £76
Caliper Life Sciences Inc. - Financial and Strategic Analysis Review
June 2009 £76
AutoImmune Inc. - Financial and Strategic Analysis Review
June 2009 £76
Avigen, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Athersys, Inc. - Financial and Strategic Analysis Review
June 2009 £76
AstraZeneca PLC - Financial and Strategic Analysis Review
June 2009 £76
Arpida Ltd. - Financial and Strategic Analysis Review
June 2009 £76
AspenBio Pharma, Inc. - Financial and Strategic Analysis Review
June 2009 £76
BioDelivery Sciences International, Inc. - Financial and Strategic Analysis Review
June 2009 £76
BioSante Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
June 2009 £76
CML Healthcare Income Fund - Financial and Strategic Analysis Review
June 2009 £76
CVS Caremark Corporation - Financial and Strategic Analysis Review
June 2009 £76
CIGNA Corporation - Financial and Strategic Analysis Review
June 2009 £76
Biodel Inc. - Financial and Strategic Analysis Review
June 2009 £76
BioSphere Medical, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Bionovo, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Biovail Corp - Financial and Strategic Analysis Review
June 2009 £76
Omnicare, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Owens & Minor, Inc. - Financial and Strategic Analysis Review
June 2009 £76
OSI Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Noven Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Nissan Chemical Industries, Ltd. - Financial and Strategic Analysis Review
June 2009 £76
Novavax, Inc. - Financial and Strategic Analysis Review
June 2009 £76
PDL BioPharma, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Pain Therapeutics, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Salix Pharmaceuticals, Ltd. - Financial and Strategic Analysis Review
June 2009 £76
Santarus, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Rigel Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Res-Care, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Par Pharmaceutical Companies, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Quest Diagnostics Incorporated - Financial and Strategic Analysis Review
June 2009 £76
Neurogen Corporation - Financial and Strategic Analysis Review
June 2009 £76
Nabi Biopharmaceuticals - Financial and Strategic Analysis Review
June 2009 £76
Manhattan Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Maxygen, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Magellan Health Services, Inc. - Financial and Strategic Analysis Review
June 2009 £76
MDRNA, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Lotus Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
June 2009 £76
MAP Pharmaceuticals - Financial and Strategic Analysis Review
June 2009 £76
MediciNova, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Medivation, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Mymetics Corporation - Financial and Strategic Analysis Review
June 2009 £76
NPS Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Mylan Inc. - Financial and Strategic Analysis Review
June 2009 £76
Molecular Insight Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Metabasis Therapeutics, Inc. - Financial and Strategic Analysis Review
June 2009 £76
MethylGene Inc - Financial and Strategic Analysis Review
June 2009 £76
Savient Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Sunesis Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Cadence Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
June 2009 £76
GlaxoSmithKline plc - Financial and Strategic Analysis Review
June 2009 £76
CHRISTUS Health - Strategic Analysis Review
June 2009 £76
Arrow International, Inc. - Strategic Analysis Review
June 2009 £76
Micromet, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Sanofi-Aventis - Financial and Strategic Analysis Review
June 2009 £76
ISTA Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Ipsen S.A. - Financial and Strategic Analysis Review
June 2009 £76
Standard Life plc - Financial and Strategic Analysis Review
June 2009 £76
Vital Signs, Inc. - Strategic Analysis Review
June 2009 £76
Novo Nordisk A/S - Financial and Strategic Analysis Review
June 2009 £76
Millipore Corporation - Financial and Strategic Analysis Review
June 2009 £76
Keryx Biopharmaceuticals, Inc. - Financial and Strategic Analysis Review
June 2009 £76
LifeCycle Pharma A/S - Financial and Strategic Analysis Review
June 2009 £76
Intuitive Surgical, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Bayer AG - Financial and Strategic Analysis Review
June 2009 £76
Vertex Pharmaceuticals Incorporated - Financial and Strategic Analysis Review
June 2009 £76
ViroPharma Incorporated - Financial and Strategic Analysis Review
June 2009 £76
VIVUS, Inc. - Financial and Strategic Analysis Review
June 2009 £76
UnitedHealth Group Incorporated - Financial and Strategic Analysis Review
June 2009 £76
SuperGen, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Tenet Healthcare Corporation - Financial and Strategic Analysis Review
June 2009 £76
Warner Chilcott Limited - Financial and Strategic Analysis Review
June 2009 £76
Waters Corporation - Financial and Strategic Analysis Review
June 2009 £76
Amgen Inc. - Financial and Strategic Analysis Review
June 2009 £76
Antares Pharma, Inc. - Financial and Strategic Analysis Review
June 2009 £76
ZymoGenetics, Inc. - Financial and Strategic Analysis Review
June 2009 £76
WellPoint, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Watson Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Lexicon Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
June 2009 £76
La Jolla Pharmaceutical Company - Financial and Strategic Analysis Review
June 2009 £76
Cytokinetics, Inc - Financial and Strategic Analysis Review
June 2009 £76
DUSA Pharmaceuticals, Inc - Financial and Strategic Analysis Review
June 2009 £76
Cypress Bioscience, Inc - Financial and Strategic Analysis Review
June 2009 £76
Curis, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Cubist Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
June 2009 £76
CuraGen Corporation - Financial and Strategic Analysis Review
June 2009 £76
Depomed, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Discovery Laboratories, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Express Scripts, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Flamel Technologies S.A. - Financial and Strategic Analysis Review
June 2009 £76
Endo Pharmaceuticals Holdings Inc. - Financial and Strategic Analysis Review
June 2009 £76
Elan Corporation, plc - Financial and Strategic Analysis Review
June 2009 £76
Dyax Corp. - Financial and Strategic Analysis Review
June 2009 £76
EPIX Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Crucell N.V. - Financial and Strategic Analysis Review
June 2009 £76
Cougar Biotechnology, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Celesio AG - Financial and Strategic Analysis Review
June 2009 £76
Celgene Corporation - Financial and Strategic Analysis Review
June 2009 £76
Cardiome Pharma Corp - Financial and Strategic Analysis Review
June 2009 £76
Callisto Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Boiron SA - Financial and Strategic Analysis Review
June 2009 £76
CV Therapeutics, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Cell Therapeutics, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Celldex Therapeutics, Inc. - Financial and Strategic Analysis Review
June 2009 £76
CombinatoRx, Incorporated - Financial and Strategic Analysis Review
June 2009 £76
Cortex Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Columbia Laboratories Inc. - Financial and Strategic Analysis Review
June 2009 £76
Chelsea Therapeutics International, Ltd. - Financial and Strategic Analysis Review
June 2009 £76
Cephalon, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Chattem, Inc. - Financial and Strategic Analysis Review
June 2009 £76
GTC Biotherapeutics, Inc. - Financial and Strategic Analysis Review
June 2009 £76
GTx, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Idenix Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Idera Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
June 2009 £76
IR Biosciences Holdings, Inc. - Financial and Strategic Analysis Review
June 2009 £76
IMS Health Incorporated - Financial and Strategic Analysis Review
June 2009 £76
ICAgen Inc - Financial and Strategic Analysis Review
June 2009 £76
IDM Pharma, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Insmed Incorporated - Financial and Strategic Analysis Review
June 2009 £76
InterMune, Inc. - Financial and Strategic Analysis Review
June 2009 £76
King Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
June 2009 £76
LCA-Vision Inc. - Financial and Strategic Analysis Review
June 2009 £76
Kindred Healthcare, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Karo Bio - Financial and Strategic Analysis Review
June 2009 £76
Isis Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Jazz Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Human Genome Sciences, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Hikma Pharmaceuticals - Financial and Strategic Analysis Review
June 2009 £76
Genta Incorporated - Financial and Strategic Analysis Review
June 2009 £76
GeoVax Labs, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Genmab AS - Financial and Strategic Analysis Review
June 2009 £76
Genentech, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Gedeon Richter Plc. - Financial and Strategic Analysis Review
June 2009 £76
Genaera Corporation - Financial and Strategic Analysis Review
June 2009 £76
H Lundbeck AS - Financial and Strategic Analysis Review
June 2009 £76
Hana Biosciences, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Hemispherx Biopharma, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Heska Corp - Financial and Strategic Analysis Review
June 2009 £76
Helix BioMedix, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Health Net, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Health Management Associates, Inc. - Financial and Strategic Analysis Review
June 2009 £76
APP Pharmaceuticals, Inc. - Strategic Analysis Review
June 2009 £76
Antigenics, Inc. - Financial and Strategic Analysis Review
June 2009 £76
Private healthcare market in Poland 2009
Development forecast for 2009-2011 Plus: Non-public hospitals in Poland database
May 2009 £1460
Good Clinical Practice
A Question & Answer Reference Guide 2009
May 2009 £30
Antisense Therapeutics Limited - Financial and Strategic Analysis Review
April 2009 £76
Apria Healthcare Group Inc. - Financial and Strategic Analysis Review
April 2009 £76
Arana Therapeutics Limited - Financial and Strategic Analysis Review
April 2009 £76
Asahi Kasei Corporation - Financial and Strategic Analysis Review
April 2009 £76
AtheroGenics, Inc. - Financial and Strategic Analysis Review
April 2009 £76
Astellas Pharma Inc. - Financial and Strategic Analysis Review
April 2009 £76
Amarin Corporation plc - Financial and Strategic Analysis Review
April 2009 £76
Yakult Honsha Co., Ltd. - Financial and Strategic Analysis Review
April 2009 £76
Agenix ltd. - Financial and Strategic Analysis Review
April 2009 £76
AXM Pharma, Inc. - Financial and Strategic Analysis Review
April 2009 £76
AVANIR Pharmaceuticals - Financial and Strategic Analysis Review
April 2009 £76
Accentia Biopharmaceuticals, Inc. - Financial and Strategic Analysis Review
April 2009 £76
International Travel and Health 2009
April 2009 £15
Auriga Laboratories Inc. - Financial and Strategic Analysis Review
April 2009 £76
Advanced Proteome Therapeutics Corp. - Financial and Strategic Analysis Review
April 2009 £76
Allergy Therapeutics plc - Financial and Strategic Analysis Review
April 2009 £76
Avita Medical Ltd - Financial and Strategic Analysis Review
April 2009 £76
Winn-Dixie Stores, Inc. - Financial and Strategic Analysis Review
April 2009 £76
Wipro Limited - Financial and Strategic Analysis Review
April 2009 £76
Cerebos Pacific Limited - Financial and Strategic Analysis Review
April 2009 £76
Cobalis Corporation - Financial and Strategic Analysis Review
April 2009 £76
Corgenix Medical Corporation - Financial and Strategic Analysis Review
April 2009 £76
Community Health Systems, Inc. - Financial and Strategic Analysis Review
April 2009 £76
Cadence Pharmaceuticals - Financial and Strategic Analysis Review
April 2009 £76
CSL Ltd - Financial and Strategic Analysis Review
April 2009 £76
BTG International Ltd - Financial and Strategic Analysis Review
April 2009 £76
Wyeth - Financial and Strategic Analysis Review
April 2009 £76
Barr Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
April 2009 £76
Bayer Schering Pharma AG - Financial and Strategic Analysis Review
April 2009 £76
Bioxel Pharma Inc. - Financial and Strategic Analysis Review
April 2009 £76
Biota Holdings Ltd. - Financial and Strategic Analysis Review
April 2009 £76
Avalon Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
April 2009 £76
STADA Arzneimittel AG - Financial and Strategic Analysis Review
April 2009 £76
Generex Biotechnology Corporation - Financial and Strategic Analysis Review
April 2009 £76
Genelabs Technologies, Inc. - Financial and Strategic Analysis Review
April 2009 £76
GammaCan International Inc - Financial and Strategic Analysis Review
April 2009 £76
Genetic Technologies Limited - Financial and Strategic Analysis Review
April 2009 £76
GeoPharma, Inc. - Financial and Strategic Analysis Review
April 2009 £76
Immucor, Inc. - Financial and Strategic Analysis Review
April 2009 £76
Henry Schein, Inc. - Financial and Strategic Analysis Review
April 2009 £76
Favrille, Inc. - Financial and Strategic Analysis Review
April 2009 £76
Evotec Aktiengesellschaft - Financial and Strategic Analysis Review
April 2009 £76
Clinical Data, Inc. - Financial and Strategic Analysis Review
April 2009 £76
Chugai Pharmaceutical Co. Ltd - Financial and Strategic Analysis Review
April 2009 £76
Derma Sciences, Inc. - Financial and Strategic Analysis Review
April 2009 £76
Emageon Inc. - Financial and Strategic Analysis Review
April 2009 £76
Endovasc, Inc. - Financial and Strategic Analysis Review
April 2009 £76
Endocare, Inc. - Financial and Strategic Analysis Review
April 2009 £76
Indevus Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
April 2009 £76
Introgen Therapeutics, Inc. - Financial and Strategic Analysis Review
April 2009 £76
OXIS International, Inc. - Financial and Strategic Analysis Review
April 2009 £76
North American Scientific, Inc. - Financial and Strategic Analysis Review
April 2009 £76
PerkinElmer, Inc. - Financial and Strategic Analysis Review
April 2009 £76
Rite Aid Corporation - Financial and Strategic Analysis Review
April 2009 £76
Coventry Health Care, Inc. - Financial and Strategic Analysis Review
April 2009 £76
Rockwell Medical Technologies, Inc. - Financial and Strategic Analysis Review
April 2009 £76
Nanogen, Inc. - Financial and Strategic Analysis Review
April 2009 £76
Minrad International, Inc. - Financial and Strategic Analysis Review
April 2009 £76
KYOWA HAKKO KOGYO Co., Ltd. - Financial and Strategic Analysis Review
April 2009 £76
Inyx, Inc. - Financial and Strategic Analysis Review
April 2009 £76
Laboratory Corporation of America Holdings - Financial and Strategic Analysis Review
April 2009 £76
Mediware Information Systems, Inc. - Financial and Strategic Analysis Review
April 2009 £76
Meridian Bioscience, Inc. - Financial and Strategic Analysis Review
April 2009 £76
Mentor Corporation - Financial and Strategic Analysis Review
April 2009 £76
Teijin Limited - Financial and Strategic Analysis Review
April 2009 £76
Daiichi Sankyo Company, Ltd - Financial and Strategic Analysis Review
April 2009 £76
Takeda Pharmaceutical Company Limited - Financial and Strategic Analysis Review
April 2009 £76
Tercica, Inc. - Financial and Strategic Analysis Review
April 2009 £76
Teva Pharmaceutical Industries Limited - Financial and Strategic Analysis Review
April 2009 £76
Myriad Genetics, Inc. - Financial and Strategic Analysis Review
April 2009 £76
Takara Holdings Inc. - Financial and Strategic Analysis Review
April 2009 £76
NeoPharm, Inc. - Financial and Strategic Analysis Review
April 2009 £76
Solvay SA - Financial and Strategic Analysis Review
April 2009 £76
Mitsubishi Tanabe Pharma Corporation - Financial and Strategic Analysis Review
April 2009 £76
MicroIslet Inc - Financial and Strategic Analysis Review
April 2009 £76
MacroChem Corp. - Financial and Strategic Analysis Review
April 2009 £76
Lorus Therapeutics Inc - Financial and Strategic Analysis Review
April 2009 £76
Matrixx Initiatives, Inc. - Financial and Strategic Analysis Review
April 2009 £76
Med Gen Inc. - Financial and Strategic Analysis Review
April 2009 £76
Meldex International PLC - Financial and Strategic Analysis Review
April 2009 £76
Meiji Seika Kaisha, Ltd. - Financial and Strategic Analysis Review
April 2009 £76
Neose Technologies, Inc. - Financial and Strategic Analysis Review
April 2009 £76
Shire Plc - Financial and Strategic Analysis Review
April 2009 £76
Pfizer Inc. - Financial and Strategic Analysis Review
April 2009 £76
PSS World Medical, Inc. - Financial and Strategic Analysis Review
April 2009 £76
Progenics Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
April 2009 £76
Protherics PLC - Financial and Strategic Analysis Review
April 2009 £76
SYSCO Corporation - Financial and Strategic Analysis Review
April 2009 £76
Publix Super Markets, Inc. - Financial and Strategic Analysis Review
April 2009 £76
Oramed Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
April 2009 £76
Onyx Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
April 2009 £76
Sciele Pharma, Inc. - Financial and Strategic Analysis Review
April 2009 £76
Nippon Kayaku Co., Ltd. - Financial and Strategic Analysis Review
April 2009 £76
Schwarz Pharma AG - Financial and Strategic Analysis Review
April 2009 £76
OPG Groep - Financial and Strategic Analysis Review
April 2009 £76
Ono Pharmaceutical Co., Ltd. - Financial and Strategic Analysis Review
April 2009 £76
Schering-Plough Corporation - Financial and Strategic Analysis Review
April 2009 £76
Lonza Group Ltd - Financial and Strategic Analysis Review
April 2009 £76
Lipid Sciences, Inc. - Financial and Strategic Analysis Review
April 2009 £76
HEALTHWAYS, INC - Financial and Strategic Analysis Review
April 2009 £76
GW Pharmaceuticals plc - Financial and Strategic Analysis Review
April 2009 £76
Virbac Corporation - Financial and Strategic Analysis Review
April 2009 £76
Humana Inc. - Financial and Strategic Analysis Review
April 2009 £76
IMUGENE LIMITED - Financial and Strategic Analysis Review
April 2009 £76
IMAGENETIX, INC - Financial and Strategic Analysis Review
April 2009 £76
Forest Laboratories, Inc. - Financial and Strategic Analysis Review
April 2009 £76
Enzon Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
April 2009 £76
Dainippon Sumitomo Pharma Co., Ltd. - Financial and Strategic Analysis Review
April 2009 £76
Ceapro Inc. - Financial and Strategic Analysis Review
April 2009 £76
Denki Kagaku Kogyo Kabushiki Kaisha - Financial and Strategic Analysis Review
April 2009 £76
E.I. du Pont de Nemours and Company - Financial and Strategic Analysis Review
April 2009 £76
Eisai Co., Ltd. - Financial and Strategic Analysis Review
April 2009 £76
ENZO BIOCHEM, INC - Financial and Strategic Analysis Review
April 2009 £76
Unitika LTD. - Financial and Strategic Analysis Review
April 2009 £76
Iasis Healthcare LLC - Financial and Strategic Analysis Review
April 2009 £76
Kuraray Co., Ltd. - Financial and Strategic Analysis Review
April 2009 £76
UCB Group - Financial and Strategic Analysis Review
April 2009 £76
General Practice Medical Services in Australia
IBISWorld Industry Report
April 2009 £360
Lannett Company, Inc. - Financial and Strategic Analysis Review
April 2009 £76
LifeCycle Pharma AS - Financial and Strategic Analysis Review
April 2009 £76
Lescarden Inc. - Financial and Strategic Analysis Review
April 2009 £76
Keryx Biopharmaceuticals - Financial and Strategic Analysis Review
April 2009 £76
Kendle International Inc. - Financial and Strategic Analysis Review
April 2009 £76
Immtech Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
April 2009 £76
ImClone Systems Incorporated - Financial and Strategic Analysis Review
April 2009 £76
ImmunoGen, Inc. - Financial and Strategic Analysis Review
April 2009 £76
Immunomedics, Inc. - Financial and Strategic Analysis Review
April 2009 £76
Japan Tobacco Inc. - Financial and Strategic Analysis Review
April 2009 £76
Nursing Homes in Australia
IBISWorld Industry Report
April 2009 £360
Cyanotech Corporation - Financial and Strategic Analysis Review
April 2009 £76
Ramsay Health Care Limited - Financial and Strategic Analysis Review
April 2009 £76
Akzo Nobel N.V. - Financial and Strategic Analysis Review
April 2009 £76
Alchemia Limited - Financial and Strategic Analysis Review
April 2009 £76
A Practical Guide to Licensing Herbal Medicinal Products
First Edition
April 2009 £250
Emergency & Other Outpatient Care Centers in the US
IBISWorld Industry Report
April 2009 £395
Biomerica, Inc. - Financial and Strategic Analysis Review
April 2009 £76
Akesis Pharmaceuticals Inc. - Financial and Strategic Analysis Review
April 2009 £76
Home Care Providers in the US
IBISWorld Industry Report
April 2009 £395
Alfacell Corporation - Financial and Strategic Analysis Review
April 2009 £76
Alkermes, Inc. - Financial and Strategic Analysis Review
April 2009 £76
Alliance Pharmaceutical Corp. - Financial and Strategic Analysis Review
April 2009 £76
Specialist Doctors in the US
IBISWorld Industry Report
April 2009 £395
Avexa Limited - Financial and Strategic Analysis Review
April 2009 £76
Agilent Technologies Inc. - Financial and Strategic Analysis Review
April 2009 £76
Avitar, Inc. - Financial and Strategic Analysis Review
April 2009 £76
Healthcare Communication
First Edition
April 2009 £29.95
BioTime, Inc. - Financial and Strategic Analysis Review
April 2009 £76
Aeolus Pharmaceuticals, Inc. - Financial and Strategic Analysis Review
April 2009 £76
Agfa-Gevaert N.V. - Financial and Strategic Analysis Review
April 2009 £76
Bioniche Life Sciences - Financial and Strategic Analysis Review
April 2009 £76
Advanced Viral Research Corp. - Financial and Strategic Analysis Review
April 2009 £76
Foodborne Disease Outbreaks. Guidelines for Investigation and Control
April 2009 £15
Advanced Cell Technology, Inc. - Financial and Strategic Analysis Review
April 2009 £76
Acusphere, Inc. - Financial and Strategic Analysis Review
April 2009 £76
CEL-SCI Corporation - Financial and Strategic Analysis Review
April 2009 £76
Substance Abuse & Mental Health Facilities in the US
IBISWorld Industry Report
April 2009 £395
Air Products and Chemicals, Inc. - Financial and Strategic Analysis Review
April 2009 £76
Biotron Limited - Financial and Strategic Analysis Review
April 2009 £76
Industry Guide to Good Hygiene Practice: Retail
April 2009 £10
General Hospitals in Australia
IBISWorld Industry Report
April 2009 £360
Private healthcare market in Central and Eastern Europe 2009
March 2009 £2145
Quintiles Transnational Corp. - Strategic Analysis Review
March 2009 £76
Radiation Therapy Services, Inc. - Strategic Analysis Review
March 2009 £76
Ratiopharm direct GmbH - Strategic Analysis Review
March 2009 £76
Provena Health - Strategic Analysis Review
March 2009 £76
NewYork- Presbyterian Hospital - Strategic Analysis Review
March 2009 £76
Resurrection Health Care - Strategic Analysis Review
March 2009 £76
Partners HealthCare System, Inc. - Strategic Analysis Review
March 2009 £76
Premera Blue Cross - Strategic Analysis Review
March 2009 £76
Providence Health System - Strategic Analysis Review
March 2009 £76
Purdue Pharma L.P. - Strategic Analysis Review
March 2009 £76
Vanguard Health Systems, Inc. - Strategic Analysis Review
March 2009 £76
The Regence Group - Strategic Analysis Review
March 2009 £76
Trinity Health - Strategic Analysis Review
March 2009 £76
New York City Health and Hospitals Corporation - Strategic Analysis Review
March 2009 £76
Wellmont Health System - Strategic Analysis Review
March 2009 £76
Sutter Health - Strategic Analysis Review
March 2009 £76
Spectrum Health System - Strategic Analysis Review
March 2009 £76
SSM Health Care System Inc. - Strategic Analysis Review
March 2009 £76
Scripps Health - Strategic Analysis Review
March 2009 £76
Sisters of Mercy Health System - Strategic Analysis Review
March 2009 £76
Roche Holding Ltd - Strategic Analysis Review
March 2009 £76
Kinray, Inc. - Strategic Analysis Review
March 2009 £76
Beverly Enterprises - Strategic Analysis Review
March 2009 £76
Baylor Health Care System - Strategic Analysis Review
March 2009 £76
Barrier Therapeutics, Inc. - Strategic Analysis Review
March 2009 £76
Biotech Holdings Ltd. - Strategic Analysis Review
March 2009 £76
Blue Cross Blue Shield of Michigan - Strategic Analysis Review
March 2009 £76
Accommodation for the Aged in Australia
IBISWorld Industry Report
March 2009 £360
Catholic Health Initiatives - Strategic Analysis Review
March 2009 £76
Blue Cross and Blue Shield of Massachusetts, Inc. - Strategic Analysis Review
March 2009 £76
Axcan Pharma Inc. - Strategic Analysis Review
March 2009 £76
Ardent Health Services LLC - Strategic Analysis Review
March 2009 £76
Asia-Pacific Enterprise Communications in the Hospitality
March 2009 £7320
Pediatric Health Care Products and Services
March 2009 £2960
Retail Clinics and The in-Store Healthcare Market 2009
Bright Spot in The Current Economy?
March 2009 £2135
AAIPharma Inc. - Strategic Analysis Review
March 2009 £76
Accredo Health Group, Inc - Strategic Analysis Review
March 2009 £76
AlphaRx, Inc. - Strategic Analysis Review
March 2009 £76
Alliance Boots GmbH - Strategic Analysis Review
March 2009 £76
Actavis Group hf. - Strategic Analysis Review
March 2009 £76
Catholic Health Services of Long Island - Strategic Analysis Review
March 2009 £76
Chr. Hansen Holding AS - Strategic Analysis Review
March 2009 £76
Lee Memorial Health System - Strategic Analysis Review
March 2009 £76
Nursing Care Facilities in the US
IBISWorld Industry Report
March 2009 £395
Katz Group Canada Ltd. - Strategic Analysis Review
March 2009 £76
Life Care Centers of America - Strategic Analysis Review
March 2009 £76
MGI Pharma Inc - Strategic Analysis Review
March 2009 £76
Merck Serono S.A. - Strategic Analysis Review
March 2009 £76
Pathology Services in Australia
IBISWorld Industry Report
March 2009 £345
MedStar Health - Strategic Analysis Review
March 2009 £76
Intermountain Healthcare, Inc. - Strategic Analysis Review
March 2009 £76
Inova Health System - Strategic Analysis Review
March 2009 £76
Dental Services in Australia
IBISWorld Industry Report
March 2009 £345
DSM N.V. - Strategic Analysis Review
March 2009 £76
Ambulance Services in the US
IBISWorld Industry Report
March 2009 £395
EGIS Pharmaceuticals Plc - Strategic Analysis Review
March 2009 £76
Group Health Cooperative - Strategic Analysis Review
March 2009 £76
InNexus Biotechnology Inc. - Strategic Analysis Review
March 2009 £76
ISTA Pharmaceuticals, Inc. - Strategic Analysis Review
March 2009 £76
Mountain States Health Alliance - Strategic Analysis Review
March 2009 £76
Texas Health Resources Inc. - Strategic Analysis Review
March 2009 £76
Dentists in the US
IBISWorld Industry Report
March 2009 £395
Specialty Hospitals in the US
IBISWorld Industry Report
March 2009 £395
Psychiatric Hospitals in Australia
IBISWorld Industry Report
February 2009 £345
Community Health Centres in Australia
IBISWorld Industry Report
February 2009 £345
Podiatrists & Other Health Care Practitioners in the US
IBISWorld Industry Report
February 2009 £395
Chiropractors in the US
IBISWorld Industry Report
February 2009 £395
Negotiating The Emerging Biosimilars Landscape
Key Developments in The Regulatory Environment
February 2009 £2025
Optometry and Optical Dispensing in Australia
IBISWorld Industry Report
February 2009 £345
Technology Transfer Strategies: Maximizing the returns from new technologies
February 2009 £2025
Diagnostic Imaging Services in Australia
IBISWorld Industry Report
February 2009 £345
Anthrax in Humans and Animals
February 2009 £24
Retirement Communities in the US
IBISWorld Industry Report
January 2009 £395
The 100 Biggest Acute Hospitals In Europe
January 2009 £595
The Epigenetics Healthcare R&D, Products and Commercial Implications
Tools, Technologies, Equipment, Opportunities & Emerging WW Market Outlook
January 2009 £1025
Optometrists in the US
IBISWorld Industry Report
December 2008 £395
Medical Supplies Wholesaling in the US
IBISWorld Industry Report
December 2008 £395
Global Medical Tourism
December 2008 £2075
European Hospital Register, The
Ongoing £1500
Chiropractic Services in Australia
IBISWorld Industry Report
November 2008 £435
Why Do Drugs Fail?
November 2008 £995
Physiotherapy Services in Australia
IBISWorld Industry Report
November 2008 £435
Clinical Laboratory Services Market
(Growth Opportunities, Competitive Analysis and Competitor Profiles)
November 2008 £1525
MarketWatch: Health Roundup
November 2008 £215
Stakeholder Insight: Osteoporosis
Generic alendronate further establishes oral bisphosphonates as gold standard
October 2008 £8000
MarketWatch: Health Round-up
October 2008 £215
North American Fetal and Neonatal Patient Monitoring Markets
October 2008 £2970
RNA therapy: the next big thing after monoclonal antibodies?
October 2008 £4000
Strategic Perspectives: Antidyslipidemics Current market is not conducive for growth
October 2008 £8000
Access to Hospital Pharmaceutical Markets in the United Kingdom
September 2008 £850
Western Europe, Healthcare Sector Pulse, April-June 2008
September 2008 £880
Sales Force Effectiveness
September 2008 £4000
World Healthcare Security Market
September 2008 £3960
Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
September 2008 £8000
British National Formulary
September 2008 £27.95
Financial Deals Industry Tracker
Pharmaceuticals and Healthcare August 2008 (Analysis of Merger and Acquisition (M&A), Private Equity, Venture Financing, Private Placement, Initial Public Offering (Ipo), and Secondary Offering Deals)
September 2008 £265
Medical Tourism Facts and Figures 2008
September 2008 £600
Cardiovascular Biomarkers: Players, products and prospects (Volume III)
August 2008 £595
Cancer, CNS & Cardiovascular Biomarkers: Players, products and prospects
August 2008 £1495
CNS Biomarkers: Players, products and prospects (Volume II)
August 2008 £595
Cancer Biomarkers: Players, products and prospects (Volume I)
August 2008 £595
Telemedicine Gets a Big Boost from the Feds
August 2008 £2745
Forecast Insight: Dyslipidemia - Genericization and negative trial data drive market shrinking
August 2008 £7600
Forecast Insight: Antidiabetics - Switching to new molecule antidiabetics drives market growth
August 2008 £7600
Commercial Insight: Select Herpes Viruses and Human Papilloma Virus
Non-Biologic Interventions for Oral and Genital Herpes, Cytomegalovirus Infection, Herpes Zoster and Genital Warts
August 2008 £7600
Big Pharma M&A Analysis to 2012 - Surveying the growth rate landscape
August 2008 £3800
Commercial Insight: Antihormonal Therapy Cancer Brands
Careful Lifecycle Management Needed to Preserve Brand Dominance
August 2008 £7600
Commercial Insight: HIV - The battle for market share is getting fiercer
August 2008 £7600
Forecast Insight: Multiple Sclerosis
Tysabri to prevail despite safety setbacks
August 2008 £7600
Forecast Insight: Insomnia Orexin and serotonin receptor modulators to innovate market
August 2008 £7600
Financial Deals Industry Tracker: Pharmaceuticals and Healthcare July 2008
(Analysis of Merger and Acquisition (M&A), Private Equity, Venture Financing, Private Placement, Initial Public Offering (Ipo), and Secondary Offering Deals)
August 2008 £265
U.S. and Worldwide Monoclonal Antibody Medicine
Current Status and Future Trends
August 2008 £670
Health Care Equipment & Supplies in Canada
July 2008 £180
Health Care Equipment & Supplies in the United Kingdom
July 2008 £180
Health Care Equipment & Supplies in the United States
July 2008 £180
Health Care Equipment & Supplies in Europe
July 2008 £180
Health Care Equipment & Supplies in Belgium
July 2008 £180
Health Care Equipment & Supplies in Asia-Pacific
July 2008 £180
Global Health Care Equipment & Supplies
July 2008 £180
Health Care Equipment & Supplies in China
July 2008 £180
Health Care Equipment & Supplies in France
July 2008 £180
Health Care Equipment & Supplies in Japan
July 2008 £180
Health Care Equipment & Supplies in Italy
July 2008 £180
Health Care Equipment & Supplies in Germany
July 2008 £180
Health Care Equipment & Supplies in the Netherlands
July 2008 £180
Health Care Equipment & Supplies in Spain
July 2008 £180
Commercial Insight: Targeted Therapy Cancer Brands
High Growth Market Will See Eight New Blockbusters by 2017
July 2008 £7600
Commercial Insight: Cytotoxic Therapy Cancer Brands
Looming Patent Expiries Limit Market Growth
July 2008 £7600
Bristol-Myers Squibb Co.: PharmaVitae Profile
July 2008 £3010
Novo Nordisk A/S: PharmaVitae Profile
July 2008 £3010
Generic Series: Optimizing Brand Lifecycle Management
Winning Strategies to Maximize Revenue in The Face of Growing Generic Competition
July 2008 £3800
Pipeline Insight: Insulin Antidiabetics
Return to Injections Alternative Delivery Methods Fall by The Wayside
July 2008 £6000
Argentina Pharmaceuticals and Healthcare Report Q3 2008
July 2008 £425
Stakeholder Opinions: Diagnostics in Neurology
Predictive Biomarkers Expand Drug Revenues
July 2008 £2005
Bon Secours Health System, Inc. Healthcare
Managed Care & Hospitals SWOT Report
July 2008 £76
Upmc Healthcare
Managed Care & Hospitals SWOT Report
July 2008 £76
Group Health Incorporated Healthcare
Managed Care & Hospitals SWOT Report
July 2008 £76
Allina Hospitals and Clinics Healthcare
Managed Care & Hospitals SWOT Report
July 2008 £76
Ssm Health Care System Inc. Healthcare
Managed Care & Hospitals SWOT Report
July 2008 £76
Premera Blue Cross Healthcare
Managed Care & Hospitals SWOT Report
July 2008 £76
Banner Health Healthcare
Managed Care & Hospitals SWOT Report
July 2008 £76
Radiation Therapy Services, Inc. Healthcare
Managed Care & Hospitals SWOT Report
July 2008 £76
Adventist Health System Healthcare
Managed Care & Hospitals SWOT Report
July 2008 £76
Horizon Healthcare Services, Inc. Healthcare
Managed Care & Hospitals SWOT Report
July 2008 £76
Universal American Corp. Healthcare
Managed Care & Hospitals SWOT Report
July 2008 £76
MedStar Health Healthcare
Managed Care & Hospitals SWOT Report
July 2008 £76
The Regence Group Healthcare
Managed Care & Hospitals SWOT Report
July 2008 £76
The Cleveland Clinic Foundation Healthcare
Managed Care & Hospitals SWOT Report
July 2008 £76
Partners HealthCare System, Inc. Healthcare
Managed Care & Hospitals SWOT Report
July 2008 £76
Triple-S Management Corporation Healthcare
Managed Care & Hospitals SWOT Report
July 2008 £76
Provena Health Healthcare
Managed Care & Hospitals SWOT Report
July 2008 £76
Mountain States Health Alliance Healthcare
Managed Care & Hospitals SWOT Report
July 2008 £76
Detroit Medical Center Healthcare
Managed Care & Hospitals SWOT Report
July 2008 £76
Commercial and Pipeline Insight
Vaccines for Adults and The Elderly - New Blockbuster Opportunities Ahead
July 2008 £7700
Commercial and Pipeline Insight
Vaccines for Adults and The Elderly - New Blockbuster Opportunities Ahead
July 2008 £7700
Iowa Health System Healthcare
Managed Care & Hospitals SWOT Report
July 2008 £76
Resurrection Health Care Healthcare
Managed Care & Hospitals SWOT Report
July 2008 £76
Stakeholder Opinions
Novel Therapeutic Approaches in Cardiovascular Medicine - Lack of Market Prospects for Biologics Expose An Opportunity for Cell and Gene Therapies
July 2008 £3800
Cvs Caremark Corporation Healthcare
Managed Care & Hospitals SWOT Report
July 2008 £76
Scripps Health Healthcare
Managed Care & Hospitals SWOT Report
July 2008 £76
Cigna Corporation Healthcare
Managed Care & Hospitals SWOT Report
July 2008 £76
Carolinas Healthcare System Healthcare
Managed Care & Hospitals SWOT Report
July 2008 £76
Long-Term Care Market
Nursing Homes, Home Care, Hospice Care, and Assisted Living
July 2008 £1230
Stakeholder Insight
Asthma - over-Prescribing Is Common in Intermittent and Mild Forms of Asthma
July 2008 £7600
Financial Deals Industry Tracker: Pharmaceuticals and Healthcare
(Analysis of Monthly Deal Activity, along with The Trend for The Last Six Months for Merger and Acquisition (M&A), Private Equity, Venture Financing, Private Placement, Initial Public Offering (Ipo), and Secondary Offering Deals)
June 2008 £265
Asian Medical Tourism Analysis
2008-2012
June 2008 £430
Allergan, Inc. Healthcare - Medical Equipment SWOT Report
May 2008 £76
Advanced Ocular Systems Limited Healthcare - Medical Equipment SWOT Report
May 2008 £76
Aethlon Medical, Inc. Healthcare - Medical Equipment SWOT Report
May 2008 £76
ADM Tronics Unlimited, Inc. Healthcare - Medical Equipment SWOT Report
May 2008 £76
Unomedical Holding as Healthcare - Medical Equipment SWOT Report
May 2008 £76
Acrux Limited Healthcare - Medical Equipment SWOT Report
May 2008 £76
Adaltis Inc. Healthcare - Medical Equipment SWOT Report
May 2008 £76
Vivolution A/S Healthcare - Medical Equipment SWOT Report
May 2008 £76
Accellent Inc. Healthcare - Medical Equipment SWOT Report
May 2008 £76
Abcam plc. Healthcare - Medical Equipment SWOT Report
May 2008 £76
Global Health Care Supplies
May 2008 £230
China Membrane Market Report
2007-2008
April 2008 £615
Emerging Medical Tourism
Thailand 2008
April 2008 £800
The Pharmaceutical Industry 2008
Current and Future Trends and Strategic Issues Shaping Pharma
March 2008 £3010
Impact of Pharmacogenomics on Public Healthcare Policy
Educating Patients, Payors and Healthcare Providers
March 2008 £1995
Private healthcare market in Poland 2008
Development forecasts for > 2008-2010
March 2008 £950
Non Voice BPO in Healthcare
March 2008 £600
Health 2.0 and Telecare for The Elderly
January 2008 £195
Surgical Robot Market Shares, Market Strategies, and Market Forecasts, 2008-2014
January 2008 £2015
Medical Tourism 2008
The World-wide Business Guide
December 2007 £1500
Premium Company Profile: DURECT Corporation
November 2007 £265
Growing 'Out of Pocket' Healthcare Market
Spending on Surgeries, Pharmaceuticals and Other Healthcare Services
November 2007 £1000
Growing 'Out of Pocket' Healthcare Market
Spending on Surgeries, Pharmaceuticals and Other Healthcare Services
November 2007 £2225
Stakeholder Insight: Acute Stroke - TPA spurs infrastructure changes for the better
Healthcare
October 2007 £7600
Commercial Insight: Cardiovascular market overview
Raft of patent expires threaten blockbusters
October 2007 £7600
Commercial Insight: Antithrombotics
Market expands as disease management focuses on prevention
October 2007 £7600
Healthcare Opportunities for Food Ingredient Manufacturers
October 2007 £1825
Indian System of Medicine Industry Report
October 2007 £400
Snapshots UK Private Healthcare Services 2007
September 2007 £150
Healthcare Technology Telehealth's Increasing Role In Healthcare (Review Report)
September 2007 £1795
Indian Health Insurance
September 2007 £600
Retail Clinics, The Emerging Market for Convenience and In-Store Healthcare
September 2007 £1825
The Current Status and Development Direction of Chinese Hospitals
August 2007 £120
Health Care Equipment & Supplies
Global Industry Guid
August 2007 £525
Future of Biosimilars, The
Key opportunities & emerging therapies
August 2007 £1495
Specialist Medical Services in Australia
IBISWorld Industry Report
July 2007 £430
Ambulance Services in Australia
IBISWorld Industry Report
July 2007 £405
Home Health Care Services in the US
IBISWorld Industry Report
July 2007 £395
Other Outpatient Care Centers in the US
IBISWorld Industry Report
July 2007 £395
Pipeline/Commercial Insight: Antihypertensives New class opportunity offset by key patent expiries
July 2007 £7600
Pipeline Insight: Upper GI Disorders - Generics will limit pipeline profit
July 2007 £6000
Patient Empowerment
Empowered Patients Can Change Healthcare Outcomes And Impact The Pharmaceutical Industry
July 2007 £3000
Hospitals (Except Psychiatric Hospitals) in Australia
IBISWorld Industry Report
June 2007 £430
Pipeline/Commercial Insight: Supportive Care in Oncology
Significant growth opportunities exist in new supportive care indications
June 2007 £7600
China Medicated Health Product Industry Report
2007
June 2007 £275
Telehealth Spending in North America and Europe Through 2012
Interactive Model
June 2007 £7915
The Global Anti-Infectives Market Outlook to 2011
June 2007 £1495
Outlook for RNAi, 2007
siRNA and miRNA in biology, diagnostics and therapeutics
June 2007 £1495
Snapshots UK Healthcare Services 2007
May 2007 £150
Chinese Medical Insurance System in a Dilemma
May 2007 £92
General Hospitals in China
IBISWorld Industry Report
May 2007 £380
U.S. Market for Home Care Products, 5th Edition
May 2007 £2435
Family Planning Centers in the US
IBISWorld Industry Report
April 2007 £395
Psychiatric and Substance Abuse Hospitals in the US
IBISWorld Industry Report
April 2007 £395
Other Residential Care Facilities in the US
IBISWorld Industry Report
April 2007 £395
China Blood Product Industry Report, 2006-2007
April 2007 £245
Business Trends Healthcare Technology
Understanding your Healthcare Customer (Customer Focus)
March 2007 £1795
Residential Mental Health and Substance Abuse Facilities in the US
IBISWorld Industry Report
March 2007 £395
Enabling Translational Medicine with BI (Technology Focus)
March 2007 £1000
General Medical and Surgical Hospitals in the US
IBISWorld Industry Report
March 2007 £395
2007 Trends to Watch: Pharmaceutical Technology
March 2007 £947.5
2007 Trends to Watch: Healthcare Technology
February 2007 £947.5
Remaining Competitive in Digital Imaging (Strategy Focus)
February 2007 £947.5
Reducing Medical Error and Improving Diagnostics through Digital Imaging (Review Report)
February 2007 £1795
Community Care Facilities for the Elderly in the US
IBISWorld Industry Report
February 2007 £395
All Other Ambulatory Health Care Services in the US
IBISWorld Industry Report
February 2007 £395
Health and Wellness Healthcare Products in Spain
February 2007 £650
Patient Education and Direct-to-Patient Communication
February 2007 £2680
Addressing the Challenges of Consumer-driven Healthcare (Review Report)
January 2007 £1795
Healthcare Technology Quarterly Briefing Q4 2006
January 2007 £1000
Residential Care Services n.e.c. in Australia
IBISWorld Industry Report
January 2007 £415
Non-Residential Care Services n.e.c. in Australia
IBISWorld Industry Report
January 2007 £460
2007 Worldwide Nursing Care Facilities Industry Report
January 2007 £120
2007 Worldwide Medical & Surgical Hospitals Industry Report
January 2007 £120
2007 Worldwide Health & Medical Insurance Carriers Industry Report
January 2007 £120
2007 Worldwide Home Health Care Services Industry Report
January 2007 £120
Indian Healthcare Services Industry Report
January 2007 £400
Health and Wellness Healthcare Products in Mexico
January 2007 £650
Health and Wellness Healthcare Products in Netherlands
December 2006 £650
Health and Wellness Healthcare Products in Russia
December 2006 £650
Health and Wellness Healthcare Products in Finland
December 2006 £650
Health and Wellness Healthcare Products in Sweden
December 2006 £650
Health and Wellness Healthcare Products in Brazil
December 2006 £650
Health and Wellness Healthcare Products in Denmark
December 2006 £650
Health and Wellness Healthcare Products in Norway
December 2006 £650
Health and Wellness Healthcare Products in Ireland
December 2006 £650
Opportunities in Medical Tourism in India (2007)
December 2006 £240
International and Expatriate Health Insurance
December 2006 £1500
Health and Wellness Healthcare Products in Switzerland
November 2006 £650
Health and Wellness Healthcare Products in Australia
November 2006 £650
Health and Wellness Healthcare Products in Canada
November 2006 £650
Health and Wellness Healthcare Products in Hong Kong, China
November 2006 £650
Health and Wellness Healthcare Products in India
November 2006 £650
Health and Wellness Healthcare Products in Indonesia
November 2006 £650
Health and Wellness Healthcare Products in Austria
November 2006 £650
Health and Wellness Healthcare Products in Belgium
November 2006 £650
Health and Wellness Healthcare Products in South Korea
November 2006 £650
Health and Wellness Healthcare Products in Germany
November 2006 £650
Health and Wellness Healthcare Products in China
November 2006 £650
Helping Healthcare Organizations Compete in a Consumer-driven Environment (Customer Focus)
November 2006 £1000
Chinese Markets for Health Care
November 2006 £2440
2007 U.S. Home Health Care Services Industry Report
October 2006 £91
2007 U.S. Health & Medical Insurance Carriers Industry Report
October 2006 £91
2007 U.S. Medical & Surgical Hospitals Industry Report
October 2006 £91
2007 U.S. Nursing Care Facilities Industry Report
October 2006 £91
Health Services n.e.c. in Australia
IBISWorld Industry Report
September 2006 £405
Patients as Consumers
Understanding the Increasing Consumer Level of Influence in Healthcare
August 2006 £2195
Women's Health
Worldwide Prescription Drug Markets
August 2006 £1200
Women's Health
Worldwide Prescription Drug Markets
August 2006 £2380
Mobility Aids & Accessories Worldwide
A Market Strategy Report
June 2006 £1215
Role of the Private Sector in the European Healthcare Market, The
June 2006 £2500
Snapshots US Nursing Home Care 2006
May 2006 £150
Snapshots US Healthcare Services 2006
May 2006 £150
Snapshots US Hospitals 2006
May 2006 £150
Snapshots US Home Healthcare 2006
May 2006 £150
Health and Wellness Healthcare Products in France
May 2006 £650
Hospital Supply Chain Management
Sector Snapshot
May 2006 £305
European Hospital Purchasing Practices
Sector Snapshot
April 2006 £305
Robotics and Orthopedic Surgery
Sector Snapshot
April 2006 £305
Outpatient Mental Health and Substance Abuse Centers in the US
IBISWorld Industry Report
April 2006 £395
Specialty (except Psychiatric and Substance Abuse) Hospitals in the US
IBISWorld Industry Report
April 2006 £395
Offices of Mental Health Practitioners (except Physicians) in the US
IBISWorld Industry Report
April 2006 £395
Health and Wellness Healthcare Products in Hong Kong
April 2006 £650
The Changing Patient-Physician Relationship Part 2
The Physician's Perspective
January 2006 £2195
Residential Mental Retardation Facilities in the US
IBISWorld Industry Report
January 2006 £395
The Changing Patient-Physician Relationship Part 1
The Patient's Perspective
January 2006 £2195
Health and Wellness Healthcare Products in Thailand
January 2006 £650
Health and Wellness Healthcare Products in Greece
January 2006 £650
Health and Wellness Healthcare Products in Japan
January 2006 £650
Health and Wellness Healthcare Products in the UK
January 2006 £650
Health and Wellness Healthcare Products in Italy
January 2006 £650
Health and Wellness Healthcare Products in the Netherlands
December 2005 £650
Reissuing pharmaceuticals in the NHS
Challenging the chain of trust
October 2005 £600
Snapshots US Healthcare Services 2005
April 2005 £150
Snapshots US Hospitals 2005
April 2005 £150
Snapshots US Nursing Home Care 2005
April 2005 £150
Snapshots US Home Healthcare 2005
April 2005 £150
Snapshots UK Healthcare Services 2005
April 2005 £150
Essentials of Economic Evaluation in Healthcare
January 2005 £25.95
An Assessment of Current Healthcare IT Application Profiles
and the Future Outlook in Europe
January 2005 £1335
Continuous Improvement in the Healthcare Manufacturing Industry
A Practical Guide
September 2003 £110
Healthcare in a Recession
(OTC, Generics, Out of Pocket Spending, Healthcare Legislation, Retail Clinics, Outsourcing and Other Topics)
March 2003 £1215
Handbook of Pharmacy Healthcare
Diseases and patient advice, 2nd Edition
August 2002 £39.95
UK Private Healthcare Market Development Report
July 2001 £600
UK Domiciliary Healthcare Market Development Report
July 2001 £600
UK Dentistry Market Development Report
June 2001 £600
UK Complimentary & Alternative Medicines Market Development Report
June 2001 £600
UK Vitamins & Mineral Supplements
May 2001 £600
UK Public Expenditure on Health
May 2001 £600
UK Health & Fitness Clubs Market Development Report
April 2001 £600
UK Residential Care for the Elderly Market Development Report
April 2001 £600